ID: ALA2087735

Max Phase: Preclinical

Molecular Formula: C24H27FN2OS

Molecular Weight: 410.56

Molecule Type: Small molecule

Representations

Canonical SMILES:  CSc1ccc(/C=C2/C(C)=C(CC(=O)NCCN(C)C)c3cc(F)ccc32)cc1

Standard InChI:  InChI=1S/C24H27FN2OS/c1-16-21(13-17-5-8-19(29-4)9-6-17)20-10-7-18(25)14-23(20)22(16)15-24(28)26-11-12-27(2)3/h5-10,13-14H,11-12,15H2,1-4H3,(H,26,28)/b21-13-

Standard InChI Key:  CYQWBRMWTGBWJA-BKUYFWCQSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 410.56

Molecular Weight (Monoisotopic): 410.1828

AlogP: 4.94

#Rotatable Bonds: 7

Polar Surface Area: 32.34

Molecular Species: BASE

HBA: 3

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 3

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 8.51

CX LogP: 4.26

CX LogD: 3.12

Aromatic Rings: 2

Heavy Atoms: 29

QED Weighted: 0.66

Np Likeness Score: -1.24

References

1. Chennamaneni S, Zhong B, Lama R, Su B..  (2012)  COX inhibitors Indomethacin and Sulindac derivatives as antiproliferative agents: synthesis, biological evaluation, and mechanism investigation.,  56  [PMID:22940705] [10.1016/j.ejmech.2012.08.005]

2. Mathew B, Hobrath JV, Connelly MC, Kiplin Guy R, Reynolds RC..  (2017)  Diverse amide analogs of sulindac for cancer treatment and prevention.,  27  (20): [PMID:28935266] [10.1016/j.bmcl.2017.09.022]

3. Mathew B, Snowden TS, Connelly MC, Guy RK, Reynolds RC..  (2018)  A small diversity library of α-methyl amide analogs of sulindac for probing anticancer structure-activity relationships.,  28  (12): [PMID:29776741] [10.1016/j.bmcl.2018.05.023]

Source

Source(1):

• Scientific Literature